← Back to Browse

Codexis, Inc.

CDXS • Healthcare

Compare

About Codexis, Inc.

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services.

Current Price
$2.43
Market Cap
$220M

Quality Assessment

Codexis, Inc. is a high-risk healthcare company with a Compass Score of 16. Poor quality metrics and high risk. Not one for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Sell
Analysts
3
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
๐Ÿ”’
EPS Beat Streak
๐Ÿ”’
Net Upgrades (180d)
๐Ÿ”’

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.